Infection by zidovudine-resistant HIV-1 compromises the virological response to stavudine in a drug-naive patient [2]

AIDS

Volumn 14, Issue 16, 2000, Pages 2632-2633

  De Ronde, Anthony ^a   Van Dooren, Maaike ^a   De Rooij, Esther ^a   Van Gemen, Bob ^b   Lange, Joep ^a   Goudsmit, Jaap ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b Primagen   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARAGINE; ASPARTIC ACID; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; ZIDOVUDINE;

ANTIVIRAL ACTIVITY; CROSS RESISTANCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LETTER; PHYLOGENY; PRIORITY JOURNAL; SEROCONVERSION; VIRUS MUTATION; VIRUS RESISTANCE;

ANTI-HIV AGENTS; DRUG RESISTANCE, MICROBIAL; HIV INFECTIONS; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; MUTATION; PHENOTYPE; REVERSE TRANSCRIPTASE INHIBITORS; STAVUDINE; ZIDOVUDINE;

EID: 0033730441     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200011100-00038     Document Type: Letter

References (5)

1. Fifth mutation in human immunodeficiency virus type 1 reverse transcriptase contributes to the development of high-level resistance to zidovudine
2. Recombinant virus assay: A rapid, phenotypic assay for assessment of drug susceptibility of human immunodeficiency virus type 1 isolates
3. Emergence of zidovudine and multidrug-resistance mutations in the HIV-1 reverse transcriptase gene in therapy-naive patients receiving stavudine plus didanosine combination therapy. STADI Group
4. Mutations conferring resistance to zidovudine diminish the antiviral effect of stavudine plus didanosine
5. Evidence of stavudine-related phenotypic resistance among zidovudine-pretreated HIV-1-infected subjects receiving a therapeutic regimen of stavudine plus lamivudine